CD33 and acute myeloid leukemia: In conclusion, this study verified the presence of CD11b+CD33+HLA−DR− blasts which resembled MDSC in the BM of newly diagnosed AML patients and demonstrated their ability to suppress the immune functions of T cells by increasing iNOS and ARG1 expression.